LuTran Pharmaceuticals
LuTran is a pharmaceutical research company headquartered in Silicon Valley with the objective of discovering and developing novel medicines for debilitating viral and neurological diseases: from AIDS through biosafety level 4 viruses, including Ebola hemorrhagic fever and Alzheimer’s.
History
LuTran was founded in 2016 and is directed by Ronald Griffith, Ph.D., the company’s Director and Chief Science Officer. He is a senior executive with over 30 years of experience in the complete drug development process with a focus on virology and neurological diseases. Ronald has published over 150 patents and publications.
LuTran has multiple compounds in development against the viruses of HIV/AIDS, Ebola, RSV, VZV and . Drug discovery efforts focus on improving intrinsic potency through stronger hydrophobic synergies in the target receptor, consequently improving efficacy and enhancing safety through maximizing specific hydrophobic interactions.
History
LuTran was founded in 2016 and is directed by Ronald Griffith, Ph.D., the company’s Director and Chief Science Officer. He is a senior executive with over 30 years of experience in the complete drug development process with a focus on virology and neurological diseases. Ronald has published over 150 patents and publications.
LuTran has multiple compounds in development against the viruses of HIV/AIDS, Ebola, RSV, VZV and . Drug discovery efforts focus on improving intrinsic potency through stronger hydrophobic synergies in the target receptor, consequently improving efficacy and enhancing safety through maximizing specific hydrophobic interactions.
Comments